Nanobiotix (NASDAQ:NBTX) Hits New 1-Year High – Time to Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) hit a new 52-week high during trading on Saturday . The stock traded as high as $31.62 and last traded at $31.04, with a volume of 86067 shares traded. The stock had previously closed at $27.51.

Analyst Ratings Changes

Several brokerages have issued reports on NBTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. TD Cowen started coverage on Nanobiotix in a research note on Friday, February 6th. They issued a “buy” rating on the stock. Guggenheim raised their price target on Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Nanobiotix currently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Nanobiotix Price Performance

The firm’s 50 day simple moving average is $22.88 and its two-hundred day simple moving average is $19.48.

Institutional Trading of Nanobiotix

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new stake in shares of Nanobiotix during the fourth quarter valued at approximately $390,000. Marshall Wace LLP bought a new stake in Nanobiotix during the 4th quarter valued at $220,000. Optiver Holding B.V. purchased a new stake in Nanobiotix during the 3rd quarter valued at $101,000. Finally, Royal Bank of Canada grew its holdings in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares during the last quarter. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.